

Research Paper

Optimized circular RNA vaccines for superior cancer immunotherapy

Hongwu Yu^{1,2*}, Yifan Wen^{1,2*}, Wenqian Yu^{1,2}, Liang Lu^{1,2}, Yu Yang^{1,2}, Chengye Liu^{1,2}, Zhixiang Hu^{1,2}, Zhuting Fang^{3,4✉}, Shenglin Huang^{1,2✉}

1. Department of Integrative Oncology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
3. Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Key Laboratory of Translational Cancer Medicine, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, 350014, China.
4. Department of Interventional Radiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China.

*These authors contributed equally to the manuscript.

✉ Corresponding authors: Shenglin Huang, Ph.D, Prof. E-mail: slhuang@fudan.edu.cn; Zhuting Fang, Ph.D, Prof. E-mail: ztfang@fjzlhospital.com.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <https://ivyspring.com/terms> for full terms and conditions.

Received: 2024.10.05; Accepted: 2024.12.10; Published: 2025.01.02

Abstract

Rationale: Circular RNA (circRNA) has gained attention as a promising platform for mRNA vaccines due to its stability, sustained protein expression, and intrinsic immunostimulatory properties. This study aimed to design and optimize a circRNA cancer vaccine platform by screening for efficient internal ribosome entry sites (IRES) and enhancing circRNA translation efficiency for improved cancer immunotherapy.

Methods: We screened 29 IRES elements to identify the most efficient one for immune cell translation, ultimately discovering the *Enterovirus A* (EV-A) IRES. Using SHAPE-MaP technology, we analyzed the secondary structure of circRNA and introduced targeted mutations and deletions to optimize translation efficiency. Additionally, we investigated the regulatory roles of spacer sequences and microRNA recognition sites in circRNA design and examined the mechanisms behind IRES-mediated translation initiation.

Results: The EV-A IRES was identified as the most efficient for immune cell translation. Structural modifications and optimization of spacer sequences enhanced the translation efficiency of circRNA. Comparative studies demonstrated that circRNA vaccines induced stronger T cell immune responses and exhibited superior tumor prevention and therapeutic efficacy compared to traditional linear mRNA vaccines.

Conclusion: The optimized tumor antigen circRNA vaccine platform offers a stable, efficient alternative to conventional mRNA vaccines for cancer immunotherapy, with enhanced immune responses and improved therapeutic outcomes. This work lays the foundation for developing circRNA-based vaccines as a novel strategy for cancer treatment.

Keywords: Circular RNA; Cancer vaccine; Tumor neoantigen; Internal ribosome entry sites (IRES); Human papillomavirus (HPV) cancer vaccine

Introduction

Immunotherapy has emerged as a highly effective strategy in cancer treatment, gaining widespread recognition in the field of oncology [1]. Among the various forms of immunotherapy,

vaccines have been explored for cancer prevention and treatment for several decades. However, it is only in recent years that mRNA-based cancer vaccines have shown promising clinical outcomes [2,3]. This

advancement can be attributed, in part, to the rapid deployment of mRNA vaccine technology during the COVID-19 pandemic [4], which significantly accelerated the clinical research and development of mRNA cancer vaccines. mRNA is now considered one of the most promising platforms for cancer vaccines for several key reasons. First, mRNA vaccines have demonstrated an excellent safety profile, as evidenced by the large-scale administration of COVID-19 mRNA vaccines. Second, mRNA has intrinsic immunostimulatory properties, and mRNA vaccines have shown superior immunogenicity compared to DNA, protein, and peptide vaccines. Finally, mRNA vaccines can be rapidly designed and manufactured, making them particularly well-suited for the development of personalized neoantigen cancer vaccines. These attributes position mRNA as a highly advantageous platform for advancing cancer vaccine development [5].

Extensive research on nucleotide modifications, cap analogs, and RNA sequence optimization has substantially enhanced the pharmacological potential of traditional linear mRNA. Currently, 5'-cap 1 mRNAs with 1-methyl-pseudouridine (m1 ψ) [6] modification, optimal 5' and 3' untranslated sequences (UTRs) [7,8], and polyadenylate (polyA) length [9,10] have been shown to yield superior translation efficiency and stability. Additional strategies to enhance linear mRNA include refining purification protocols to minimize double-stranded RNA (dsRNA) contamination [11,12], optimizing the secondary structure of the coding sequence [13,14], and incorporating branched polyA tails [15]. However, these approaches either yield marginal improvements or substantially increase the complexity of production processes without fundamentally enhancing druggability. Furthermore, although m1 ψ modification is essential for achieving optimal translation efficiency and stability, recent study has indicated that m1 ψ modification may induce frameshift translation [16], thereby presenting potential adverse effects. From a vaccine platform perspective, m1 ψ modification significantly diminishes the intrinsic immunogenicity of mRNA, potentially undermining its capacity to elicit an effective immune response. On the other hand, unmodified linear mRNA exhibits suboptimal expression levels, rendering it a less favorable option for vaccine development. Consequently, the development of tumor vaccines utilizing novel mRNA platforms might address these challenges and offer unforeseen advantages.

Due to its high stability and naturally lacking termini, circular RNA (circRNA) is considered a promising mRNA drug platform [17]. In recent years,

the permuted intron-exon (PIE)-based RNA circularization method has been optimized, making circRNA synthesis simpler and more efficient [18]. Most synthetic circRNA incorporates a viral Internal Ribosome Entry Site (IRES) to initiate protein translation [18–20]. Consequently, IRES translation efficiency is a key determinant of circRNA protein expression levels, which determines the efficacy of circRNA therapeutics. While previous studies have shown that IRES screening and adjacent sequence optimization can significantly enhance circRNA translation efficiency [20], there has been limited exploration of highly efficient IRES in specific cell types, such as immune cells. Moreover, viral IRES function through multiple domains that recruit translation initiation factors and IRES trans-acting factor (ITAFs) [21–23], suggesting that systematic optimization of these domains could further enhance IRES function. On the other hand, synthetic circRNA, due to the presence of exogenous sequences and large secondary structures, can be recognized by cellular pattern recognition receptors, thereby triggering immune responses [24–26], which could pose challenges in drug development. However, in the context of cancer immunotherapy, drugs with immunostimulatory properties may more effectively induce tumor-targeting immunity. Therefore, stable and immunostimulatory circRNA is likely to be an ideal tumor vaccine platform. Studies have demonstrated that engineered circRNA vaccines can efficiently induce adaptive immunity, resulting in significant tumor suppression in animal models [27,28]. Nonetheless, more research is needed to compare the immune induction capability and tumor treatment efficacy of circRNA vaccines with those of well-established linear mRNA vaccines.

In this study, we aim to design a circRNA platform specifically suited for tumor vaccines by optimizing the key translational element, IRES, and systematically comparing it with conventional linear mRNA vaccines *in vitro* and animal models. First, we identified an IRES from *Enterovirus* genus EV-A virus, which demonstrated highest translation efficiency in immune cell lines. We employed SHAPE-MaP (selective 2' hydroxyl acylation analyzed by primer extension and mutational profiling) technology to resolve its structure and further optimized and streamlined its sequence while screening for the best-performing UTR elements in the circRNA platform. Additionally, we explored the mechanism of IRES-mediated translation initiation, discovering that IRES-mediated cap-independent translation might compete with cap-dependent translation for initiation factors. Ultimately, the circRNA vaccine exhibited superior antigen-specific immune induction

and tumor suppression effects in both *in vitro* and *in vivo* animal models compared to traditional linear mRNA vaccines.

Results

Screening for highly efficient IRES

CircRNA cannot initiate translation via the 5' cap-dependent mechanism, instead relying on IRES or m6A modifications to initiate translation [29]. To enhance the expression levels of circRNA, particularly in immune cells for application as tumor vaccines, we first screened IRES elements with high translation efficiency. Previous studies have shown that viral IRES elements achieve the highest translation efficiency on circRNA [18,20]. Thus, our candidate IRES elements were primarily derived from viruses. We screened a total of 29 IRES elements (Figure 1A, Figure S1A, and Table S1), including 22 type I, 2 type II, 2 type III viral IRES, and 3 mammalian cell-derived IRES [30–32]. Initially, we utilized dual-luciferase reporter plasmids to compare the cap-independent translation efficiency of these IRES elements in the mouse dendritic cell line DC2.4 and HEK293T cells (Figure 1A). Consistent with previous studies [18,20], type I IRES elements generally exhibited stronger translation efficiency compared to other types and mammalian IRES elements (Figure 1A). As anticipated, the translation efficiency of IRES elements varied between different cell types. For example, the translation efficiency of HRV-C20 was approximately twice that of CVB3 in HEK293T cells, but only 20% of CVB3's efficiency in DC2.4 cells. This screening revealed that the IRES from *Enterovirus A* (EV-A) exhibited the highest translation efficiency in both cell lines.

To further validate the performance of highly efficient IRES elements in circRNA, we incorporated the seven highest-expressing IRES elements into circRNA constructs, synthesizing circular firefly luciferase (FLUC) mRNA using the previously reported PIE circularization method [18] (Figure 1B and Figure S1B). The expression profiles of these IRES elements in circRNA differed from those in the dual-luciferase reporter system, potentially due to unexpected splicing events in plasmid-based system [33], or differences in the spatial configuration of IRES elements in circRNA compared to linear RNA [34]. Nonetheless, both in the dual-luciferase plasmid and circRNA contexts, the IRES from EV-A demonstrated the highest relative translation efficiency (Figure 1B). The IRES elements from HRV-B3 and CVB3, previously reported for their high translation efficiency [18,20], also performed well but were slightly less efficient than the EV-A IRES in both

DC2.4 and HEK293T cells (Figure 1C).

To investigate the adaptability of the EV-A IRES to different coding sequences, we constructed circular EGFP mRNA and compared EGFP expression levels in HEK293T, DC2.4, and the human monocytic cell line THP-1 (Figure 1D, Figure S1C). Our results confirmed that the EV-A IRES maintained the highest translation efficiency. These findings indicate that the EV-A IRES is a robust translation element for circRNA, adaptable to different coding sequences and exhibiting high translation efficiency in mouse and human immune cell lines.

Structural analysis and sequence optimization of EV-A IRES

Previous studies have elucidated that the five structural domains (domains II to VI) of type I viral IRES recruit translation initiation factors and ITAFs to initiate translation [23]. Specifically, domain V directly interacts with eukaryotic initiation factors eIF4G and eIF4A, facilitating the assembly of the 48S ribosomal complex. Domains II and IV recruit hnRNP A1 and PCBP1/2 respectively, stabilizing the IRES structure and aiding in the recruitment of initiation factors. Ribosomal scanning occurs within domain VI, while the function of domain III remains less well understood. We hypothesized that mutating and simplifying the structural domains of the EV-A IRES might stabilize its structure and enhance translation efficiency. Therefore, we employed SHAPE-MaP technology [35] to resolve the structure of the EV-A IRES, designed targeted mutations and truncations, and compared their translation efficiencies.

The SHAPE-MaP secondary structure model of the EV-A IRES revealed a typical type I IRES secondary structure, encompassing domains I to VI (Figure 2A). Notably, the EV-A IRES also exhibited a unique stem-loop structure located after domain VI, which we designated as domain VII. Sequence comparisons between EV-A and other *Enterovirus* IRES elements (Figure S2A) indicated that domains I, II, III, IV, and V are highly conserved, whereas domains VI and VII are more variable. Domain I primarily participates in viral genome replication rather than translation. Based on this analysis, our optimization strategy included mutating key functional domains and deleting less conserved or non-essential sequences.

Our approach to optimizing key functional domains was to increase the GC content of long stems to strengthen base-pairing without altering their secondary structure or critical protein-binding regions (e.g., PCBP1/2, eIF4G) [36,37]. We designed seven EV-A mutants based on this approach (Figure 2A blue dashed boxes and Table S1), incorporated them into

The statistical significance was assessed between CVB3 and other IRESs. (B) and (C) Top IRESs were cloned into circular FLUC mRNA and co-transfected with RLUC mRNA into HEK293T (B) and DC2.4 (C) cells. (B) Left panel, schematic diagram of circRNA design and circularization. Right panel, FLUC/RLUC ratio at 24 hours post transfection. (C) FLUC/RLUC ratio at 24 hours post transfection of DC2.4 cells. (D) Top IRESs were cloned into circular EGFP mRNA and screened in THP-1. Left panel, bar plot of GFP signal normalized to CVB3. Right panel, representative FACS histogram of GFP signal. Mean GFP fluorescence of $n > 100,000$ singlet cells per sample was measured by flow cytometry. Dashed line indicates mean GFP signal of EV-A. The statistical significance was assessed between EV-A and other IRESs in (B), (C) and (D). All data are mean (SD) for $n = 3$ biological replicates. One-way ANOVA, Dunnett's post-test was used to calculate the statistical significance. * $P < 0.05$ was considered statistically significant. ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$ were considered highly significant. ns, not significant.

Next, we systematically truncated the longer, non-essential sequences of EV-A, including domain I (90nt), the linker between domains I and II (30nt), domain VI (42 nt), and domain VII (32nt) (Figure 2A red dashed boxes and Table S1). Luminescence signal results indicated that truncating domains I, VI, and VII did not affect IRES translation, whereas deleting the linker significantly reduced translation efficiency (Figure 2C). To assess whether further combinations of truncations might impact IRES function, we generated EV-A mutants with domain I + VI truncations (DI+DVI), domain I+VI+VII truncations (DI+DVI+DVII) and domain I + VI truncations combined with the 5m1 mutation (DI+DVI+5m1). Interestingly, simultaneous truncation of domains I and VI significantly improved EV-A translation efficiency by approximately 50%, while additional truncation of domain VII or incorporation of the 5m1 mutation did not provide further enhancement (Figure 2D). Moreover, the translation efficiency of these three mutants is significantly higher than that of the wild-type EV-A in both DC2.4 and THP-1 cells, confirming that this improvement is cell type-independent (Figure S2B and S2C). We hypothesized that the improvement resulted from the more streamlined and stable structure with both domains I and VI truncated. To verify this hypothesis, we resolved the structure of the DI +DVI mutant. SHAPE-MaP reactivity signals within the core regions of the DI +DVI mutant were almost identical to those of the wild-type EV-A (Figure 2E). Comparing the predicted secondary structures of the DI +DVI mutant and wild-type EV-A IRES, we observed that the structures of the functional domains (domains II, III, IV, V) were perfectly preserved in the mutant. Unexpectedly, not only were the deleted structures (domains I and VI) absent, but a small stem-loop near domain II and domain VII also disappeared (Figure 2E). This result supports our hypothesis that deleting multiple non-essential structures rendered the IRES more streamlined and stable. In summary, our engineering based on SHAPE-MaP structural analysis generated a shorter (reduced from 750 nt to 618 nt) and more stable EV-A IRES with significantly enhanced translation efficiency.

Screening for spacers and regulatory elements

Although translation of circRNA is mediated by IRES, the translation efficiency and expression level of

the target protein are also significantly influenced by other sequences within the circRNA design [18,20]. For instance, residual sequences from the PIE circularization method may inhibit circRNA translation. However, incorporating spacer sequences between the IRES, CDS, and residual sequences can mitigate such inhibition [20]. Similar to the 5' UTR and 3' UTR of classical linear mRNA, spacer sequences can differentially impact the translation and stability of circRNA depending on their relative positions to the IRES and CDS. Therefore, we refer to the spacer sequences at the 5' end of the IRES and the 3' end of the CDS as the 5' Spacer and 3' UTR of the circRNA, respectively, and we screened these sequences separately (Figure 3A and Table S2).

We also utilized circular GLUC mRNA (circGLUC) to screen for optimal UTR sequences. For the spacer sequences, we compared PABP v3, apt-eIF4G [20], beta-globin 5' UTR [7], polyAC [18], and 50nt of polyadenylate (polyA50) to the control circGLUC without spacer or 3' UTR. The results indicated that polyA50 yielded the highest GLUC signal when used as the 5' Spacer (Figure 3A). For the 3' UTR, our screening included hemoglobin subunit alpha 1 (HBA1) 3' UTR, polyAC, polyA50, and beta-globin 3' UTR [7]. Additionally, considering that viral 3' UTR sequences may facilitate IRES function [38], we also included the 3' UTR sequences from CVB3, EV-A, HRV-B3, and SINV in our screening. The results showed that polyA50 was also the most effective spacer sequence in the 3' UTR position (Figure 3B). Overall, the polyA50 sequence promoted IRES function most effectively, whether used as the 5' Spacer or the 3' UTR, likely due to its simple spatial structure and its ability to recruit PABP, promoting the interaction between IRES and the translation initiation factor eIF4G.

In the design of circRNA, in addition to adding spacer sequences to promote protein expression, incorporating microRNA recognition sequences to regulate circRNA expression in specific tissues is also a meaningful strategy. miR-122 is a liver-specific microRNA highly expressed in the liver [39]. Studies have demonstrated that incorporating miR-122 recognition sites into AAV vectors successfully inhibited AAV vector expression in the liver [40]. We added sequences containing miR-122 recognition sites to the 5' Spacer or 3' UTR positions of circRNA and transfected them into the miR-122-expressing liver

cancer cell line HuH-7 (Figure 3C and Table S2). Both 1× and 3× miR-122 recognition sites in either position significantly reduced GLUC expression in HuH-7, whereas in HEK293T cells, which do not express miR-122, GLUC expression showed no significant difference compared to control circRNA without spacers (Figure 3D). This result indicates that adding

just one recognition site sequence to circRNA can achieve substantial miR-122-mediated knockdown of circRNA. These findings suggest that microRNA recognition sites can be added to circRNA to enable effective tissue-specific regulation of circRNA distribution.




Figure 2. Secondary structure and mutational modification of EV-A IRES. (A) SHAPE-MaP reactivity and secondary structure of wild-type EV-A IRES. Upper panel, SHAPE-MaP reactivity profile. Reactivities below 0.4 are colored black, reactivities between 0.4 and 0.85 are shown in orange and reactivities above 0.85 are shown in red. Light

blue blocks indicate profile of predicted structures. Lower panel, secondary structure. The nucleotide coloring indicates normalized reactivity values of ≤ 0.4 (gray), >0.4 and <0.85 (light red), and ≥ 0.85 (dark red). Bold black characters indicate structural domains. (B) Comparison of translation efficiency between artificially mutated and the wild-type EV-A IRES. (C) Comparison of translation efficiency between truncated mutants and the wild-type EV-A IRES. Mutants were constructed based on circular EV-A GLUC mRNA. Mutants and wild-type mRNAs were transfected into HEK293T, and GLUC activity was measured 24 hours post transfection. GLUC activity was normalized to wild-type EV-A. Mutations (light blue dotted boxes with linked characters) and truncations (red dotted boxes with linked characters) are indicated in (A). (D) Comparison of translation efficiency between combinational mutants (DI+DVI, DI+DVI+DVII and DI+DVI+5mI) and wild-type EV-A IRES. (E) SHAPE-MaP reactivity and secondary structure of DI+DVI mutant EV-A IRES. All data are mean (SD) for $n=3$ biological replicates. One-way ANOVA, Dunnett's post-test was used to calculate the statistical significance. $*P < 0.05$ was considered statistically significant. $**P < 0.01$, $***P < 0.001$ and $****P < 0.0001$ were considered highly significant. ns, not significant.




Figure 3. CircRNA untranslated region screening and introduction of miR122 recognition sequence. (A and B) Translation efficiency comparison of circular GLUC mRNA containing indicated spacer (A) and 3'UTR (B) in HEK293T cells. Left panel of (A), schematic diagram of insertion site of spacer/3'UTR in circRNA. (C) Schematic diagram of insertion sites of miR-122 recognition sequence in circular GLUC mRNA. (D) Translation efficiency of circular GLUC mRNA with miR-122 recognition sequence in HEK293T (Left panel) and HuH-7 (Left panel) cells. CircRNAs were transfected into HEK293T or HuH-7 cells, and GLUC activity was measured 24 hours post transfection. GLUC activity was normalized to control circRNA without Spacer or 3'UTR. All data are mean (SD) for $n=3$ biological replicates. One-way ANOVA, Dunnett's post-test was used to calculate the statistical significance. $*P < 0.05$ was considered statistically significant. $**P < 0.01$, $***P < 0.001$ and $****P < 0.0001$ were considered highly significant. ns, not significant.

Regulation of CircRNA translation and *in vitro* immune induction of CircRNA vaccine

Previous studies have indicated that the translation initiation mechanism of viral IRES differs from that of eukaryotic mRNA 5' cap. For instance, the 5' cap recruits eIF4E, followed by eIF4G, forming the eIF4F complex, which subsequently recruits the 43S pre-initiation complex [21,41]. In contrast, type I IRES recruits eIF4G with the assistance of ITAFs, bypassing the requirement for eIF4E [42]. Similarly, the translation initiation mechanism of *in vitro* transcribed circRNA with IRES is expected to differ significantly from that of *in vitro* transcribed linear mRNA with 5' cap analogs. To compare the translation initiation mechanisms of these two mRNA platforms, we designed siRNAs targeting key translation regulatory proteins, including PABP1, ITAFs PCBP1 and PCBP2, and translation initiation factors eIF4E, eIF4G1, eIF4G2, and eIF3D (Table S4).

Upon knockdown of PABP1, PCBP1, PCBP2, eIF3D, and eIF4G2, both circRNA and linear RNA translation were significantly reduced (Figure 4A, 4B). Interestingly, knockdown of cap-dependent translation initiation factors eIF4E and eIF4G1 resulted in a significant decrease in linear RNA translation but a notable increase in circRNA translation (Figure 4B). These results suggest that circRNA translation shares common regulatory proteins with cap-dependent translation, but circRNA may also compete with cellular cap-dependent translation for common initiation factors. This might require additional attention in future studies on the safety and efficacy of circRNA therapeutics. From another perspective, hijacking initiation factors specific for cap-dependent translation may further elevate circRNA translation.

We further compared the stability and immune induction capabilities of circRNA and linear mRNA to evaluate whether circRNA offers advantages in these areas. Consistent with previous studies [18,20], our circRNA exhibited prolonged and enhanced expression compared to both modified and unmodified linear mRNA (Figure 4C and Figure S3A). Additionally, some studies have reported that circRNA possesses strong immunostimulatory properties, potentially acting as an adjuvant to enhance adaptive immunity [24–27]. To assess the immune induction capability of circRNA, we transfected BMDC cells with circular, unmodified linear, and modified linear mRNA encoding the Ovalbumin (OVA) antigen (Table S3). Eight hours post-transfection, we measured the expression of BMDC activation-related genes via RT-qPCR. The results showed that BMDCs transfected with circular OVA expressed the highest levels of DC

activation-related genes (CD80, CD86, CD40), IL6 and type I interferon signal (IFN β), followed by those transfected with unmodified linear OVA, indicating that circRNA has a stronger capacity to activate DCs (Figure 4D).

Subsequently, we co-cultured BMDCs transfected with these three types of OVA mRNA with mouse spleen cells containing a small proportion of OVA-specific T cells (0.5% of all CD8⁺ T cells). Six days later, we measured the proportion of OVA-specific T cells and found that the circRNA group induced greatest proliferation of OVA-specific T cells (Figure 4E). These results demonstrate that circRNA can induce specific T cell immunity more robustly, suggesting that circRNA-based tumor vaccines may have superior efficacy compared to traditional linear mRNA vaccines.

Tumor prophylactic effects of circular RNA vaccines

To evaluate the tumor prophylactic effects of our designed circRNA platform as cancer vaccine, we selected OVA as a model antigen and established a B16F10 stable cell line expressing OVA through lentivirus infection. Mice were vaccinated with three doses of the circular or linear OVA mRNA vaccines via intravenous injection on days -27, -17, and -10 before subcutaneous inoculation with B16F10-OVA tumor cells. Blood samples were collected three days before tumor inoculation to analyze vaccine induced systematic T cell response in PBMCs (Figure 5A). Flow cytometry analysis showed that the proportion of OVA peptide (SIINFEKL) MHC tetramer-positive T cells in PBMCs was significantly higher in the three vaccinated groups compared to the untreated group, indicating that all three types of RNA vaccines successfully induced OVA-specific T cells (Figure 5B). Notably, the CircOVA and m1 ψ LinearOVA vaccines induced a higher proportion of OVA-specific T cells compared to the LinearOVA vaccine.

Further analysis of T cell subsets in PBMCs revealed that the proportions of naïve T cells were significantly lower in the CircOVA and LinearOVA groups compared to the untreated group, whereas the m1 ψ LinearOVA group showed no significant difference from the untreated group (Figure 5C). The proportion of central memory T cells was significantly higher in the CircOVA and LinearOVA groups, while all three vaccine groups exhibited a significantly higher proportion of effector T cells compared to the untreated group (Figure 5C). These results suggest that CircOVA and unmodified LinearOVA vaccines shifted overall T cell composition towards a more activated phenotype, possibly due to recognition by pattern recognition receptors in immune cells

enhanced overall antigen presentation. In contrast, the m1ψLinearOVA vaccine, with its lower intrinsic

immunostimulatory effect, imposed smaller alterations on the overall T cell subset composition.




Figure 4. CircRNA translation regulation and *in vitro* OVA-specific T cell expansion. (A and B) Translation efficiency of circular and linear GLUC mRNA after knockdown of PABP1/PCBP1/PCBP2 (A), eIF4G1/ eIF4G2/ eIF4E/ eIF3D (B). HEK293T cells were treated with siRNA targeting the indicated genes for 48 hours. Treated cells

were then transfected with circular or linear mRNA, and GLUC activity was measured 24 hours post transfection. Upper panel, GLUC activity normalized to wild-type control experiment treated with negative control siRNA. Lower panel, normalized RNA level of corresponding genes measured by qPCR. (C) GLUC activity of the HEK293T culture supernatant though day 1 to day 5 after transfection of circular, linear and m1Ψ modified linear GLUC mRNA. (D) Normalized RNA level of corresponding genes in BMDC cells after transfection of circular, linear or m1Ψ modified linear OVA mRNA. RNA level was normalized to mock transfected control group. (E) OVA-specific T cell expansion after co-culturing with BMDCs transfected with circular, linear or m1Ψ modified linear OVA mRNA. Upper panel, quantified percentages of OVA-specific T cells. Lower panel, representative flow cytometry diagram. All data are mean (SD) for n=3 biological replicates. In (A) and (B), Unpaired two-sided t-test was used to calculate the statistical significance. In (D), two-way ANOVA was used. In (E), One-way ANOVA was used. *P < 0.05 was considered statistically significant. **P < 0.01, ***P < 0.001 and ****P < 0.0001 were considered highly significant. ns, not significant.




Figure 5. Circular OVA mRNA vaccine induced effective T cell response and protective effect against B16F10-OVA tumor model. (A) Timeline of vaccination, drawing blood and monitoring of tumor volume. Mice were injected retro-orbitally with CircOVA(n=5)/LinearOVA(n=5)/ m1ΨLinearOVA(n=5) vaccine three times

(5 μ g per dose) in 17 days. 1 \times 10⁵ B16F10-OVA cells were injected subcutaneously to each mouse 10 days after the third vaccination. (B) Representative flow cytometry diagram and percentages of OVA-specific T cells in PBMC 7 days after the third vaccination. (C) Quantified percentages of naïve (CD44-CD62L+), central-memory (CD44+CD62L+) and effector/effector-memory (CD44+CD62L-) T cells within CD8+ T cells in PBMC 7 days after the third vaccination. (D) Tumor volumes until day 24 after tumor inoculation. (E) Tumor volume of individual mice until day 35. (F) Survival rate. For (D), data are mean (SEM). All other data are mean (SD). In (B) and right panel of (C), Mann-Whitney U test was used to calculate the statistical significance. In (D) and left and middle panel of (C), one-way ANOVA was used. In (F) Kaplan-Meier simple survival analysis was used to calculate the survival rate, and Log-rank (Mantel-Cox) test was used to calculate the statistical significance. *P < 0.05 was considered statistically significant. **P < 0.01, ***P < 0.001 and ****P < 0.0001 were considered highly significant. ns, not significant.

Ten days after the third vaccination, mice were subcutaneously inoculated with B16F10-OVA tumor cells, and tumor growth was monitored for 60 days post-inoculation. In the vaccinated groups, some mice did not develop tumors through the 60-day observation period (CircOVA: 4/5, m1 ψ LinearOVA: 3/5, LinearOVA: 2/5). Notably, 80% of the mice in the CircOVA group remained tumor-free, whereas all mice in the untreated group developed tumors within approximately two weeks (Figure 5E, 5F). On day 24 post-tumor inoculation, the tumor sizes in the vaccinated groups were significantly smaller than those in the untreated group, with some tumors in the untreated group reaching the humane endpoint (Figure 5D). These results demonstrate that our circRNA vaccine exhibits excellent immune activation capability, comparable antigen specific T cell induction ability to modified linear mRNA, and superior tumor prophylactic effect.

Therapeutic efficacy of circular RNA vaccines targeting tumor neoantigens and tumor-associated antigens

OVA is a highly immunogenic xenogeneic animal antigen, and therefore, the B16F10-OVA model may not accurately reflect the clinical scenario of tumor treatment. Tumor mutational neoantigens and virus-derived tumor-associated antigens are common targets in tumor vaccine development. To evaluate the therapeutic potential of the circRNA vaccines, we designed vaccines encoding a tandem of eight reported B16F10 tumor mutational neoantigens [44,45] (Figure 6A and Table S3) and an HPV E6E7 fusion protein vaccine [46] (Figure 7A and Table S3), and tested them in B16F10 and TC-1 tumor models, respectively.

Three days after subcutaneous inoculation of B16F10 cells, mice were immunized with the three types of B16-8 tandem antigen vaccines (Figure 6B). A booster immunization was administered on day 10, and tumor growth were monitored until day 21. On day 21, mice were euthanized, and spleens and tumors were collected. To assess the proportion of vaccine-induced neoantigen-specific T cells, we measured the proportion of IFN- γ + CD8+ T cells in splenocytes stimulated with BMDCs transfected with m1 ψ LinearB16 mRNA. The results showed that all three vaccine groups induced higher levels of IFN- γ + CD8+T cells, with the CircB16-8 group showing the

highest average proportion (Figure 6C). Tumor monitoring results also indicated that both CircB16 and m1 ψ LinearB16 vaccines significantly inhibited tumor growth (Figure 6D, 6E).

The TC-1 cell line, which stably expresses HPV oncogenes E6 and E7, is commonly used as an HPV-related tumor model. To evaluate the therapeutic efficacy of the HPV tumor vaccine on established tumors, we inoculated mice subcutaneously with TC-1 cells and, after 14 days (average tumor volume reached 30 mm³), administered mRNA vaccines encoding the HPV E6/E7 fusion protein via intravenous injection. Blood samples were collected seven days after the second vaccine dose (Figure 7A). Flow cytometry analysis of PBMCs revealed that the CircE6E7 vaccine induced significantly greater proportion of IFN- γ -secreting T cells in PBMCs stimulated with E6 and E7 derived peptides compared to all other groups (Figure 7B). Both the m1 ψ Linear E6E7 and Linear E6E7 vaccine induced higher proportion of antigen specific T cells compared to the control group, although these differences were not statistically significant. Consistent with the antigen-specific T cell induction results, the CircE6E7 and m1 ψ LinearE6E7 vaccines successfully eradicated the tumors, whereas the LinearE6E7 vaccine also inhibited tumor growth but to a lesser extent (Figure 7C, 7D and 7E). Taken together, these results demonstrate that the circRNA vaccines encoding tumor mutational neoantigens and HPV antigens induced stronger tumor antigen-specific T cell immunity and exhibited superior therapeutic efficacy in mice compared to conventional linear mRNA vaccines.

Discussion

To design and optimize a tumor circRNA vaccine platform, this study specifically screened for highly efficient IRESs in immune cell lines, and identified the EV-A IRES. After resolving its secondary structure, we engineered a streamlined mutant of EV-A IRES with significantly higher translation efficiency through a series of mutation and deletion assessments. We also screened for more suitable untranslated sequences to pair with our IRES and tested the introduction of microRNA recognition sites for precise regulation of circRNA. Our circRNA-encoded vaccines induced higher levels of T cell immune responses compared to conventional

linear mRNAs in both *in vitro* immune cell models and *in vivo* animal models, demonstrating strong tumor prevention and therapeutic effects.




Figure 6. CircRNA encoded neantigen vaccine induced strong neantigen specific T cell response and optimal therapeutic effect against B16F10 tumor. (A) Design of circular and linear B16F10 neantigen vaccines. Left panel, schematic diagram of the concatemer vaccine design. Signal peptide (SP) and transmembrane domain (MITD) of human MHC-I were added to augment antigen presentation. Right panel, target information of the 8 previously reported B16F10 neoantigen encoded by the vaccines. (B) Timeline of vaccination, monitoring of tumor volume and collecting tumor and spleen samples. Mice were subcutaneously inoculated with 1×10^5 B16F10 cells and vaccinated retro-orbitally with CircB16-8(n=5)/LinearB16-8 (n=5)/m1 Ψ LinearB16-8 (n=5) on day 3 and 10 (5 μ g per dose). (C) Representative flow cytometry diagram and percentages of B16-8 antigen-specific T cells in splenocyte. Splenocytes were stimulated with BMDCs transfected with m1 Ψ LinearB16-8 mRNA for 16 hours, then stained for intra-cellular IFN γ . (D) Tumors collected on day 21 and tumor volumes until day 21 after tumor inoculation. (E) Tumor volume of individual mice until day 21. For (D), data are mean (SEM). All other data are mean (SD). In (C) and (D), one-way ANOVA was used to calculate the statistical significance. *P < 0.05 was considered statistically significant. **P < 0.01, ***P < 0.001 and ****P < 0.0001 were considered highly significant.




Figure 7. Circular HPV antigen vaccine induced eradication of HPV associated TC-1 tumor model. (A) Design of circular and linear HPV E6+E7 fusion protein vaccines. Left panel, schematic diagram of the vaccine design. A fusion protein of the HPV E6, E7 oncogenes reported by previous study was used as the encoding antigen. Signal peptide (SP) and transmembrane domain (MITD) of human MHC-I were added to augment antigen presentation. Right panel, timeline of vaccination, monitoring of tumor volume and drawing blood. Mice were subcutaneously inoculated with 1x10⁵ TC-1 cells. When average tumor volume reached about 30mm³ on day 14, mice were vaccinated retro-orbitally with CircE6E7 (n=5)/Linear E6E7 (n=5)/m1 Ψ Linear E6E7 (n=5, 5 μ g per dose), and received a booster dose on day 21 (5 μ g per dose). (B) Representative flow cytometry diagram and percentages of E6E7 antigen-specific T cells in PBMC. PBMCs were stimulated with mixed MHC class I restricted E6 and E7 epitopes (2.5 μ g/ml each; EVYDFAFRDL for E6, RAHYNIVTF for E7) for 16 hours, and stained for intra-cellular IFN γ . (C) Tumor volumes until day 32 after tumor inoculation. (D) Survival rate. (E) Tumor volume of individual mice until day 39. For (C), data are mean (SEM). All other data are mean (SD). In (B) and (C), one-way ANOVA was used to calculate the statistical significance. In (D) Kaplan-Meier simple survival analysis was used to calculate the survival rate, and Log-rank (Mantel-Cox) test was used to calculate the statistical significance. *P < 0.05 was considered statistically significant. **P < 0.01, ***P < 0.001 and ****P < 0.0001 were considered highly significant.

The IRES is the primary translation initiation element in circRNA and determines the expression levels of circRNA therapeutics, making its screening and optimization a crucial step in circRNA drug development. In 2018, Wesselhoeft *et al.* compared several viral and cellular IRES elements on circRNA and identified the CVB3 IRES as the most efficient [18]. A more extensive screening and modification

was conducted by Chen *et al.* in 2023 [20], who employed a modular construction platform to compare the efficiencies of dozens of IRES elements, ultimately identifying HRV-B3 as more efficient. However, previous studies did not specifically screen for highly efficient IRES elements in immune cells for use in tumor circRNA vaccines. In our study, screening 29 IRESs elements revealed that EV-A

exhibited the highest translation efficiency in immune cell lines DC2.4 and THP-1, as well as in HEK293T cells.

We further analyzed the structure of EV-A using SHAPE-MaP technology and made targeted mutations and deletions of each domain, successfully simplifying and enhancing the translation efficiency of EV-A. Structural analysis of the simplified EV-A revealed that the key functional structures were perfectly retained, while all non-core structures, not limited to the deleted ones, disappeared. This potentially indicates that the simplified IRES became more stable, thereby improving translation efficiency. Additionally, we discovered that although the linker sequence before domain II did not form a secondary structure, its deletion significantly reduced translation efficiency, suggesting a functional role in translation. Interestingly, mutations in different sequences within the functional domains, without affecting the secondary structure, had varying impacts on translation, indicating distinct functions of these sequences. For instance, some sequences within the functional domains may be responsible for secondary structure formation while others interact with proteins or distal sequences through their specific nucleotides. Overall, our results show that IRES needs to retain only the core domains to function effectively in translation initiation, with the secondary structure and nucleotide composition of the core domains both playing crucial roles. However, our analysis of the structure and function of EV-A IRES is still limited, especially concerning the engineering and investigation of core functional domains. Future research with more comprehensive and high-throughput engineering of EV-A IRES core domains could provide a deeper understanding of the relationship between its structure and function, and further elevate its efficiency.

Moreover, we compared the translation regulation mechanisms of linear mRNA and circRNA. We found that PABP1, PCBP1, PCBP2, eIF3D, and eIF4G2 support the translation of both linear and circular mRNA. However, knockdown of cap-dependent translation initiation factors eIF4E and eIF4G1 resulted in increased circRNA translation but decreased linear mRNA translation, indicating their primary involvement in cap-dependent translation. Although eIF4G2, a member of the eIF4G family, lacks the eIF4E-binding domain present in eIF4G1 [47], it is generally considered to participate in cap-independent translation mechanisms such as IRES, CITE, and m6A [48]. However, it has also been found to affect cap-dependent translation efficiency [49], which explains why its reduction impaired translation of both RNA types. The opposite effects on

translation efficiency for the two types of RNA following eIF4E and eIF4G1 knockdown suggest competition between IRES-mediated and cap-dependent translation for downstream initiation factors. This implies that exogenous circRNA entering cells may compete with endogenous mRNA for translation initiation proteins. Similarly, exogenous linear mRNA also inevitably competes with endogenous mRNA for translation-related proteins. This could be a safety concern for both mRNA therapeutics. Nonetheless, reasonably utilizing the differences and competitive relationships in these translation mechanisms might be an effective way to further enhance circRNA translation levels.

Despite our results showing that circRNA vaccines have stronger immunostimulatory capabilities compared to linear mRNA vaccines, we did not delve into the underlying mechanisms. Notably, circRNA has a tendency to spontaneously break, making it difficult to rule out the possibility that the resulting 5'-monophosphate linear RNA fragments could trigger immune responses. In our circRNA production process, RNaseR treatment is used to remove free intron and full-length pre-RNA byproducts from the mixture, but a small amount of nicked linear RNA fragments may still remain (Figure S1B and Figure S7). Due to the spontaneous breaking of circRNA, other purification methods like High Performance Liquid Chromatography (HPLC) or gel extraction used in other studies also leave some nicked RNA fragments [18,26,50]. Previous studies have varied views on whether circRNA itself activates cellular immune responses: Wesselhoef *et al.* suggested that circRNA does not activate immune responses due to the absence of ends [51]; Chen *et al.* proposed that exogenous sequences in circRNA activate immune responses, which can be suppressed by m6A modification [24,25]; Liu *et al.* demonstrated that stem-loop structures of different lengths in circRNA have distinct effects on immune responses [26]. A recent study indicated that both circRNA itself and impurities in its production process are recognized by different pattern recognition receptors, resulting in immune activation [50]. Cells recognize exogenous RNA in various ways, including end recognition and double-stranded RNA recognition. The complex RNA double-stranded structures of the IRES in circRNA could potentially be recognized by cells, triggering immune responses [24–27]. Activation of cellular immune responses could be a disadvantage in certain application contexts. However, when dose, efficacy and safety are properly balanced, this property of circRNA could be a significant advantage in application such as cancer immunotherapy.

Several studies have recently explored the use of

circRNA to encode tumor-targeting drugs. For example, circRNA has been used to encode cytokines such as IL-15 and IL-12 for the treatment of melanoma and liver cancer, either as standalone therapies or in combination with PD-1 antibodies [51,52]. Another significant area of research is the use of circRNA as a tumor vaccine platform. Hongjian Li *et al.* were the first to develop a circRNA-based tumor vaccine, creating a lipid nanoparticle system for circRNA delivery. Their circRNA vaccine effectively induced both adaptive and innate immunity and significantly inhibited tumor growth [28]. In 2023, Laura Amaya *et al.* showed that circRNA inherently possesses adjuvant activity, effectively enhancing T-cell immune responses. Their circRNA vaccine encapsulated by charge-altering releasable transporters (CARTs) also exhibited strong anti-tumor efficacy [27]. These findings are consistent with our data in this study, confirming that circRNA can indeed enhance the immune response. Most recently, Fei Wang *et al.* designed a circRNA-based liver cancer vaccine, which exhibited more stable expression compared to linear mRNA and demonstrated superior efficacy in treating solid tumors [53]. Collectively, these studies, along with our findings, consistently support the idea that circRNA, with its stable expression and adjuvant activity, is an ideal platform for tumor vaccines.

As we highlighted above, circRNA has emerged as a promising RNA drug platform in recent years, yet it still requires significant advancements in production, safety, and efficacy research. Despite these challenges, its unique properties and promising preclinical results justify more comprehensive and in-depth investigations. Future studies should aim to elucidate the mechanisms underlying circRNA translation regulation and immune responses, as well as to advance the design and clinical applications of circRNA. It is anticipated that the advantages of circRNA drugs will soon be realized in the treatment of tumors and various other diseases.

Materials and Methods

Molecular cloning

For dual luciferase reporter assay, IRESs are chemically synthesized and cloned into a pRF plasmid between the RLUC and FLUC coding sequences. The pUC57 plasmids, inserted with the T7 promoter, Anabaena 2.0 PIE elements reported by Wesselhoeft *et al.* [18], IRESs and coding sequences through seamless cloning were used as the circRNA template plasmids. The Cloning Kit for mRNA Template (Takara Bio) was used to construct all the linear mRNA templates. The template vector in that

kit contains a T7 promoter, a human beta-globin 5' UTR, a human HBA1 3' UTR and a 105nt long poly(A) sequence. DNA fragments were synthesized by Genewitz (Suzhou, China) and amplified by PCR. ClonExpress II One Step Cloning Kit from Vazyme (Nanjing, China) were used for seamless cloning. The IRES sequences are provided in Table S1.

Luciferase reporter assay

For dual luciferase reporter assay, 100ng of pRF plasmids containing different IRESs were transfected into 10,000 HEK293T or DC2.4 cells/100 μ L per well of a 96-well plate using Hieff Trans Liposomal Transfection Reagent (Yeasen). 24 hours later, cells were lysed and luminescence counts were detected using Dual Luciferase Reporter Gene Assay Kit (Yeasen) according to manufacturer's instructions. Ratio of FLUC/RLUC counts was considered as IRES activity.

For firefly luciferase assay of circular FLUC RNA, cells were cultured in 96 well plate at the density of 5,000 cells per well. The next day, circular FLUC RNA were transfected with TransIT-mRNA Transfection Kit (Mirusbio) at 50ng per well according to manufacturer's instruction. 24 hours later, cells were lysed on ice for 5 min, both firefly and renilla luminescence counts were measured using Dual Luciferase Reporter Gene Assay Kit (Yeasen) according to manufacturer's instruction. The translation efficiency was calculated by FLUC/RLUC ratio.

For gaussia luciferase assay, cells were cultured in 96 well plate at the density of 5,000 cells per well. The next day, mRNAs were transfected with TransIT-mRNA Transfection Kit (Mirusbio) at 50ng per well according to manufacturer's instruction. 24 hours later, 20 μ L cell culture medium was taken from each well, and luminescence counts were measured using Gaussia Luciferase Reporter Gene Assay Kit (Beyotime) according to manufacturer's instruction.

circRNA and linear mRNA synthesis

For the circRNAs, PCR amplified templates were used in in-vitro transcription assay using T7 High Yield RNA Synthesis Kit (Yeasen). The reaction mixture was incubated overnight (~16 hours) at 37°C for maxim spontaneous circularization, and treated with DNase I at 37°C for 20 mins. Then 1 \times T4 RNA Ligase Reaction Buffer and 2mM (final concentration) GTP was added, and the reaction mixture was incubated at 55°C for 15min to further circularize. RNA was purified with GeneJET RNA Purification Kit, then heated at 65°C for 3min. For every 20ug purified RNA, 20U RNase R (Beyotime) and 1 \times RNase R reaction buffer was added to the reaction and

incubated at 37°C for 2 hours. CircRNA was finally purified with GeneJET RNA Purification Kit, and analyzed by 4% PAGE gel or 2% agarose gel.

For linear mRNAs used in this research, HindIII enzyme linearized plasmids were used as the template in in-vitro transcription using T7 High Yield RNA Synthesis Kit for Co-transcription (Yeasen). The mRNAs were capped with Cap1 co-transcriptionally and transcribed with a 105nt long polyA tail. After 2 hours incubation at 37°C, the reaction crudes were treated with DNase I at 37°C for 20 mins, then purified with GeneJET RNA Purification Kit (Thermo Scientific) and analyzed by 2% agarose gel.

SHAPE-MaP (selective 2' hydroxyl acylation analyzed by primer extension and mutational profiling)

Circular EVA-GLUC mRNA was analyzed by SHAPE-MaP method reported by Smola *et al.* [35]. Briefly, RNA was modified in 100mM 1-methyl-7-nitroisatoic anhydride (1M7) for 5min under 37°C, then purified with GeneJET RNA Purification Kit (Thermo Scientific). Unmodified and denatured control were prepared the same as Smola's protocol. Purified RNA was fragmented, then reverse transcribed with Hieff NGS Ultima Dual-mode mRNA Library Prep Kit (Yeasen) with some modifications including incubating under 42°C for 3 hours and adding 15 mM MnCl₂ (final concentration). cDNAs were then purified with GeneJET RNA Purification Kit (Thermo Scientific). Subsequent RNA library construction was carried out according to the manufacturer's instruction. The sequencing data in FASTQ format was subsequently analyzed by ShapeMapper program according to Smola's protocol. Secondary structure prediction constrained by SHAPE reactivity were generated using RNAstructure program.

siRNA knockdown

HEK293T cells were cultured in 24 well plates at 100,000 cells per well. siRNAs targeting corresponding proteins were transfected at 30pmol per well with Hieff Trans siRNA/miRNA reagent (Yeasen). 48 hours later, total RNAs of three of the replicate wells were extracted and assayed by RT-qPCR to analysis knockdown efficiency. mRNAs were transfected into the other three replicates, at 200ng per well with TransIT-mRNA Transfection Kit (Mirusbio). 24 hours later, 30μL cell culture medium was taken from each well to measure gaussia luciferase signal. siRNA sequences were synthesized by Hipobio (Huzhou, Zhejiang) and provided in Table S4.

RNA extraction and RT-qPCR

Total RNA was extracted using EZ-press RNA Purification Kit (EZBioscience) following the manufacturer's instructions. cDNA was synthesized from 500ng total RNA using Evo M-MLV Reverse Transcription Kit (Accurate Biotechnology, Huan) following the manufacturer's instructions. mRNA levels were quantified using SYBR Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology, Huan), normalized to *Actin*. Primer sequences are provided in Table S5. All qPCR reactions were performed on QuantStudio 5 Real-Time PCR System (Applied Biosystems).

Western blotting

Circular, modified linear and unmodified linear antigen mRNAs (OVA, B16 and E6E7) were transfected into HEK293T cells in 24-well plate at 400ng/well with TransIT-mRNA Transfection Kit (Mirusbio). 24 hours later, cells are lysed by SDS-loading buffer. Total proteins were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred on to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The membrane was next blocked with 5% non-fat milk and incubated with Anti-DYKDDDDK (flag) or Anti-actin antibodies (Proteintech). The protein bands were detected using a Tanon 5200 Chemiluminescent Imaging System (Tanon, Shanghai, China) with Omni-ECL reagents (Epizyme Biotech, China).

BMDC and T cell *in vitro* stimulation

BMDCs were generated with the method reported by Lutz *et al.* [54] For BMDC stimulation assay, BMDCs were cultured in 24 well plates at 250,000 cells per well with mGM-CSF (Peprotech) added to 4ng/mL. 6 hours later, linear or circular mRNAs were transfected at 500ng per well using CALNP mRNA *in vitro* reagent (D-nano, Beijing). 8 hours later, total RNAs were extracted and assayed by RT-qPCR.

For T cell *in vitro* stimulation, BMDCs were cultured in 48 well plates at 200,000 cells per well with mGM-CSF (Peprotech) added to 4ng/mL. 6 hours later, linear or circular OVA mRNAs were transfected at 500ng per well with CALNP mRNA *in vitro* reagent (D-nano, Beijing). 12 hours later, 1 million splenocytes with 0.5% OVA specific CD8 T cell were added to each well, and co-cultured with BMDC for 3 days. On day 3, floating cells were transferred to a new plate, with mIL-7 (Peprotech) and mIL-15 (Peprotech) added to final concentration 5 ng/mL. After another 3 days' culture, cells were analyzed by flow cytometry.

Animal model

Male C57BL/6N mice aged between 6–8 weeks were purchased from Beijing Vital River Laboratory Animal Technology. For immunization, the mice were injected retro-orbitally with 100 µL mRNA (5 µg per dose) formulated with *in vivo*-jetRNA reagent (Polyplus). B16F10-OVA cells were generated by lentiviral infection with lentivirus containing pLVX-Puro-OVAL-c plasmid purchased from Shanghai Kambio. For the B16F10-OVA model, 1×10^5 B16F10-OVA cells in 200 µL RPMI 1640 medium (without fetal bovine serum) were subcutaneously injected into the right flank of C57BL/6N mice. For the B16F10 model, 1×10^5 B16F10 cells in 200 µL RPMI 1640 medium (without fetal bovine serum) were subcutaneously injected into the right flank of C57BL/6N mice. For the HPV associated TC-1 model, 1×10^5 TC-1 cells in 200 µL RPMI 1640 medium (without fetal bovine serum) were subcutaneously injected into the right flank of C57BL/6N mice. Mice body weight and tumors were measured twice every week. Tumor volume (V) was determined by using the formula $V = L \times W^2 / 2$. All experiments were performed in accordance with protocols approved by Fudan University Experimental Animal Care Commission.

Flow cytometry analysis

For *in vitro* OVA T cell stimulation assay, the cells were stained with Fixable Viability Dye eFluor 450 (65-0863-14, eBioscience), anti-CD3 (APC-65077, Proteintech), anti-CD8a (FITC-65069, Proteintech), OVA Tetramer-SIINFEKL (PE, Helixgen Guangzhou). For OVA mRNA vaccinated mice, peripheral blood was collected through submandibular sampling and lymphocytes were separated by Mouse 1× Lymphocyte Separation Medium (DAKEWE, Shenzhen) according to the manufacturer's instruction. Cells were then stained with Fixable Viability Dye eFluor 450 (65-0863-14, eBioscience), anti-CD3 (APC-65077, Proteintech), anti-CD8a (FITC-65069, Proteintech), anti-CD44 (Proteintech), anti-CD62L (Proteintech), OVA Tetramer-SIINFEKL (PE, Helixgen Guangzhou). For B16F10 neoantigen mRNA vaccinated mice, splenocytes were co-cultured with BMDCs transfected with m1ψLinearB16 mRNA for 16 hours, with brefeldin A (5 µg/ml, Yeasen) and monensin (Yeasen) at the beginning. Then the splenocytes were stained for intra-cellular IFN γ . For HPV E6E7 mRNA vaccinated mice, cells were cultured with E6 and E7 derived peptides (5 µg/ml each, GenScript), brefeldin A (5 µg/ml, Yeasen) and monensin (Yeasen) for 16 hours, then stained for intra-cellular IFN γ . For intra-cellular IFN γ staining, cells were first stained with Fixable Viability Dye eFluor 450 (65-0863-14, eBioscience), anti-CD3

(APC-65077, Proteintech), anti-CD8a at 4°C for 30 min. Subsequently, cells were fixed and permeabilized with Intracellular Fixation and Permeabilization Buffer Set (eBioscience) according to the manufacturer's instruction, and stained with anti-IFN γ (PE, Biolegend) at room temperature for 20 min.

Capillary electrophoresis analysis of antigen CircRNA

CircRNA treated or untreated by RNaseR were analyzed by Qsep100 (BIOptic) using R1 Cartridge (BIOptic) according to the manufacturer's instruction.

Statistical analysis

All data in this study were analyzed via Graphpad Prism and presented as mean (SD) unless otherwise indicated. Two-tailed unpaired Student's t-test was used to compare two groups. One-way and two-way ANOVA tests were used to compare more than two groups. Mann-Whitney U test was applied if data sets failed the Pearson omnibus normality test ($\alpha = 0.05$). For survival curves, the data was performed via Kaplan-Meier analysis. * $P < 0.05$ was considered statistically significant. ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$ were considered highly significant. ns, not significant.

Abbreviations

mRNA: messenger RNA; IRES: internal ribosome entry sites; circRNA: circular RNA; SHAPE-MaP: selective 2' hydroxyl acylation analyzed by primer extension and mutational profiling; m1ψ: 1-methyl-pseudouridine; UTR: untranslated sequences; polyA: polyadenylate.

Supplementary Material

Supplementary figures.

<https://www.thno.org/v15p1420s1.pdf>

Supplementary tables.

<https://www.thno.org/v15p1420s2.xlsx>

Acknowledgments

This work was supported by grants from National Key Research and Development Project of China (2021YFA1300500), National Natural Science Foundation of China (82272625, 82072694), Joint Funds for the Innovation of Science and Technology, Fujian province (2023Y9320), and Financial Scheme for Young Talents Training Program of Fujian Health Industry (No. 2017-ZQN-1).

Data and code availability

The authors declare that all data supporting the

findings of this study are available within the article and its supplemental files or are available from the authors upon request.

Author contributions

S.H., H.Y. and Z.F. designed the study; H.Y. and Y.W. performed experiments and analyzed and discussed data; W.Y. performed the bioinformatics analysis; Y.Y., Z.H. and C.L. helped with the animal models; L.L. helped with the siRNA knock-down assay; H.Y. and S.H. wrote and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Competing Interests

S.H. and H.Y. are listed as inventors of the application of EV-A circRNA vaccine.

References

- Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol.* 2020; 20: 651–68.
- Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. *Nature.* 2023; 618: 144–50.
- Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. *Lancet.* 2024; 403: 632–44.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020; 383: 2603–15.
- Lorentzen CL, Haanen JB, Met Ö, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. *Lancet Oncol.* 2022; 23: e450–8.
- Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. *J Control Release.* 2015; 217: 337–44.
- Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. *Blood.* 2006; 108: 4009–17.
- Orlandini von Niessen AG, Poleganov MA, Rechner C, et al. Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. *Mol Ther.* 2019; 27: 824–36.
- Schlake T, Thess A, Fotin-Mlczek M, Kallen K-J. Developing mRNA-vaccine technologies. *RNA Biol.* 2012; 9: 1319–30.
- Grier AE, Burleigh S, Sahni J, et al. pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences. *Molecular Therapy - Nucleic Acids.* 2016; 5: e306.
- Baiersdörfer M, Boros G, Muramatsu H, et al. A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. *Molecular Therapy - Nucleic Acids.* 2019; 15: 26–35.
- Nelson J, Sorensen EW, Mintri S, et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. *Sci Adv.* 2020; 6: eaaz6893.
- Leppek K, Byeon GW, Kladwang W, et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. *Nat Commun.* 2022; 13: 1536.
- Zhang H, Zhang L, Lin A, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. *Nature.* 2023; 621: 396–403.
- Chen H, Liu D, Guo J, et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. *Nat Biotechnol.* 2024; [Online ahead of print]
- Mulrone TE, Pöyry T, Yam-Puc JC, et al. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. *Nature.* 2024; 625: 189–94.
- Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. *Signal Transduct Target Ther.* 2023; 8: 341.
- Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. *Nat Commun.* 2018; 9: 2629.
- Chen CY, Sarnow P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. *Science.* 1995; 268: 415–7.
- Chen R, Wang SK, Belk JA, et al. Engineering circular RNA for enhanced protein production. *Nat Biotechnol.* 2023; 41: 262–72.
- Yamamoto H, Unbehaun A, Spahn CMT. Ribosomal Chamber Music: Toward an Understanding of IRES Mechanisms. *Trends Biochem Sci.* 2017; 42: 655–68.
- Mailliot J, Martin F. Viral internal ribosomal entry sites: four classes for one goal. *Wiley Interdiscip Rev RNA.* 2018; 9.
- Lai M-C, Chen H-H, Xu P, Wang RYL. Translation control of Enterovirus A71 gene expression. *J Biomed Sci.* 2020; 27: 22.
- Chen YG, Kim MV, Chen X, et al. Sensing Self and Foreign Circular RNAs by Intronic Identity. *Mol Cell.* 2017; 67: 228–238.e5.
- Chen YG, Chen R, Ahmad S, et al. N6-Methyladenosine Modification Controls Circular RNA Immunity. *Mol Cell.* 2019; 76: 96–109.e9.
- Liu C-X, Guo S-K, Nan F, Xu Y-F, Yang L, Chen L-L. RNA circles with minimized immunogenicity as potent PKR inhibitors. *Mol Cell.* 2022; 82: 420–434.e6.
- Amaya L, Grigoryan L, Li Z, et al. Circular RNA vaccine induces potent T cell responses. *Proc Natl Acad Sci U S A.* 2023; 120: e2302191120.
- Li H, Peng K, Yang K, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. *Theranostics.* 2022; 12: 6422–36.
- Li M, Wang Y, Wu P, et al. Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy. *Cancer Lett.* 2023; 563: 216190.
- Xue S, Tian S, Fujii K, Kladwang W, Das R, Barna M. RNA regulons in Hox 5' UTRs confer ribosome specificity to gene regulation. *Nature.* 2015; 517: 33–8.
- Blau L, Knirsh R, Ben-Dror I, et al. Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation. *Proceedings of the National Academy of Sciences.* 2012; 109: E2875–84.
- Grover R, Candeias MM, Fähræus R, Das S. p53 and little brother p53/47: linking IRES activities with protein functions. *Oncogene.* 2009; 28: 2766–72.
- Chu J, Robert F, Pelletier J. Trans-spliced mRNA products produced from circRNA expression vectors. *RNA.* 2021; 27: 676–82.
- Xu C, Zhang L, Wang W, et al. Improving the Circularization Efficiency, Stability and Translatability of Circular RNA by circDesign. *bioRxiv.* 2023; 07.09.548293
- Smola MJ, Rice GM, Busan S, Siegfried NA, Weeks KM. Selective 2'-hydroxyl acylation analyzed by primer extension and mutational profiling (SHAPE-MaP) for direct, versatile and accurate RNA structure analysis. *Nat Protoc.* 2015; 10: 1643–69.
- Beckham SA, Matak MY, Belousoff MJ, et al. Structure of the PCBP2/stem-loop IV complex underlying translation initiation mediated by the poliovirus type I IRES. *Nucleic Acids Res.* 2020; 48: 8006–21.
- de Breyne S, Yu Y, Unbehaun A, Pestova TV, Hellen CUT. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. *Proc Natl Acad Sci U S A.* 2009; 106: 9197–202.
- Zoll J, Heus HA, van Kuppeveld FJM, Melchers WJG. The structure-function relationship of the enterovirus 3'-UTR. *Virus Res.* 2009; 139: 209–16.
- Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol.* 2004; 1: 106–13.
- Qiao C, Yuan Z, Li J, et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. *Gene Ther.* 2011; 18: 403–10.
- Hinnebusch AG. The scanning mechanism of eukaryotic translation initiation. *Annu Rev Biochem.* 2014; 83: 779–812.
- Sweeney TR, Abaeva IS, Pestova TV, Hellen CU. The mechanism of translation initiation on Type 1 picornavirus IRESs. *EMBO J.* 2014; 33(1): 76–92.
- Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. *Cancer Res.* 2012; 72: 1081–91.
- Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. *Nature.* 2015; 520: 692–6.
- Xie Q, Zhou Z-X, Li Z-L, Zeng Y. Transforming activity of a novel mutant of HPV16 E6E7 fusion gene. *Virol Sin.* 2011; 26: 206–13.
- Imataka H, Olsen HS, Sonenberg N. A new translational regulator with homology to eukaryotic translation initiation factor 4G. *EMBO J.* 1997; 16: 817–25.

47. Liu Y, Cui J, Hoffman AR, Hu J. Eukaryotic translation initiation factor eIF4G2 opens novel paths for protein synthesis in development, apoptosis and cell differentiation. *Cell Prolif.* 2022; 56: e13367.
48. Lee SH, McCormick F. p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. *EMBO J.* 2006; 25: 4008-19.
49. Cheng F, Li J, Hu C, et al. Study on the Characterization and Degradation Pattern of Circular RNA Vaccines Using an HPLC Method. *Chemosensors.* 2024; 12: 120.
50. Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG. RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo. *Mol Cell.* 2019; 74: 508-520.e4.
51. Yang J, Zhu J, Sun J, et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. *Molecular Therapy Nucleic Acids.* 2022; 30: 184-97.
52. Xu S, Xu Y, Solek NC, et al. Tumor-Tailored Ionizable Lipid Nanoparticles Facilitate IL-12 Circular RNA Delivery for Enhanced Lung Cancer Immunotherapy. *Advanced Materials.* 2024; 36: 2400307.
53. Wang F, Cai G, Wang Y, et al. Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy. *MedComm (2020).* 2024; 5: e667.
54. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J Immunol Methods.* 1999; 223(1): 77-92.